130–150 million people globally have chronic hepatitis C infection. It is a virus that infects 3.2 million Americans and the leading cause of liver transplantation in the United States. Forbes examines Merck’s $4 billion deal with Idenix Pharmaceuticals. Click here to read the article.
Merck to cut time on curing hepatitis C?
About the Author: Judy Hsieh
Judy is Senior Programs Manager at Larta. In this capacity, she leads the programs team in charge of the planning, development, and execution of various Commercialization Assistance Programs (CAPs). The Commercialization Assistance Programs help entrepreneurs transition the R&D ideas into viable products in the commercial market. Judy develops and executes key program elements, including directly oversees communications with program participants, coordinates expert mentoring and program events.